Diabetes, Vol 48, Issue 10 2090-2095, Copyright © 1999 by American Diabetes Association

ARTICLES

A protein kinase C-beta-selective inhibitor ameliorates neural dysfunction in streptozotocin-induced diabetic rats

J Nakamura, K Kato, Y Hamada, M Nakayama, S Chaya, E Nakashima, K Naruse, Y Kasuya, R Mizubayashi, K Miwa, Y Yasuda, H Kamiya, K Ienaga, F Sakakibara, N Koh and N Hotta
Third Department of Internal Medicine, Nagoya University School of Medicine, Japan. jiro@tsuru.med.nagoya-u.ac.jp

Increased protein kinase C (PKC) activity has been implicated in the pathogenesis of diabetic retinopathy and nephropathy. However, the role of PKC in diabetic neuropathy remains unclear. The present study was conducted to compare the effect of PKC inhibition by a PKC-beta-selective inhibitor, LY333531 (LY), on diabetic nerve dysfunction with that of an aldose reductase inhibitor, NZ-314 (NZ). Streptozotocin-induced diabetic rats were treated with or without LY and/or NZ for 4 weeks, and motor nerve conduction velocity (MNCV), coefficient of variation of R-R interval (CVR-R), sciatic nerve blood flow (SNBF), peak latencies of oscillatory potentials on electroretinogram, PKC activities in membranous and cytosolic fractions of sciatic nerves, and polyol contents in the tail nerves were measured. Untreated diabetic rats demonstrated delayed MNCV, decreased CVR-R, reduced SNBF, and prolonged peak latencies of oscillatory potentials. Treatment with LY as well as NZ prevented all these deficits in diabetic rats. There were no significant differences in PKC activities in membranous or cytosolic fractions of sciatic nerves between normal and diabetic rats. Treatment with neither LY nor NZ altered PKC activities. Nerve myo-inositol depletion in diabetic rats was ameliorated not only by NZ, but also by LY. These observations suggest that inhibition of PKC-beta by LY may have a beneficial effect in preventing the development of diabetic nerve dysfunction, and that this effect may be mediated through its action on the endoneurial micro-vasculature.
CiteULike    Del.icio.us    Digg    Reddit    Technorati    What's this?

This article has been cited by other articles:

				T. Shibata, K. Naruse, H. Kamiya, M. Kozakae, M. Kondo, Y. Yasuda, N. Nakamura, K. Ota, T. Tosaki, T. Matsuki, et al. Transplantation of Bone Marrow-Derived Mesenchymal Stem Cells Improves Diabetic Polyneuropathy in Rats Diabetes, November 1, 2008; 57(11): 3099 - 3107. [Abstract] [Full Text] [PDF]

				C. Toth, L. L. Rong, C. Yang, J. Martinez, F. Song, N. Ramji, V. Brussee, W. Liu, J. Durand, M. D. Nguyen, et al. Receptor for Advanced Glycation End Products (RAGEs) and Experimental Diabetic Neuropathy Diabetes, April 1, 2008; 57(4): 1002 - 1017. [Abstract] [Full Text] [PDF]

				I. G. Obrosova, O. Ilnytska, V. V. Lyzogubov, I. A. Pavlov, N. Mashtalir, J. L. Nadler, and V. R. Drel High-Fat Diet Induced Neuropathy of Pre-Diabetes and Obesity: Effects of "Healthy" Diet and Aldose Reductase Inhibition Diabetes, October 1, 2007; 56(10): 2598 - 2608. [Abstract] [Full Text] [PDF]

				C. M. Casellini, P. M. Barlow, A. L. Rice, M. Casey, K. Simmons, G. Pittenger, E. J. Bastyr III, A. M. Wolka, and A. I. Vinik A 6-Month, Randomized, Double-Masked, Placebo-Controlled Study Evaluating the Effects of the Protein Kinase C-{beta} Inhibitor Ruboxistaurin on Skin Microvascular Blood Flow and Other Measures of Diabetic Peripheral Neuropathy Diabetes Care, April 1, 2007; 30(4): 896 - 902. [Abstract] [Full Text] [PDF]

				M. J. Stevens, F. Li, V. R. Drel, O. I. Abatan, H. Kim, D. Burnett, D. Larkin, and I. G. Obrosova Nicotinamide Reverses Neurological and Neurovascular Deficits in Streptozotocin Diabetic Rats J. Pharmacol. Exp. Ther., January 1, 2007; 320(1): 458 - 464. [Abstract] [Full Text] [PDF]

				V. R. Drel, N. Mashtalir, O. Ilnytska, J. Shin, F. Li, V. V. Lyzogubov, and I. G. Obrosova The Leptin-Deficient (ob/ob) Mouse: A New Animal Model of Peripheral Neuropathy of Type 2 Diabetes and Obesity Diabetes, December 1, 2006; 55(12): 3335 - 3343. [Abstract] [Full Text] [PDF]

				E. C.M. Ho, K. S.L. Lam, Y. S. Chen, J. C.W. Yip, M. Arvindakshan, S.-I. Yamagishi, S. Yagihashi, P. J. Oates, C. A. Ellery, S. S.M. Chung, et al. Aldose Reductase-Deficient Mice Are Protected From Delayed Motor Nerve Conduction Velocity, Increased c-Jun NH2-Terminal Kinase Activation, Depletion of Reduced Glutathione, Increased Superoxide Accumulation, and DNA Damage. Diabetes, July 1, 2006; 55(7): 1946 - 1953. [Abstract] [Full Text] [PDF]

				O. Ilnytska, V. V. Lyzogubov, M. J. Stevens, V. R. Drel, N. Mashtalir, P. Pacher, M. A. Yorek, and I. G. Obrosova Poly(ADP-Ribose) Polymerase Inhibition Alleviates Experimental Diabetic Sensory Neuropathy Diabetes, June 1, 2006; 55(6): 1686 - 1694. [Abstract] [Full Text] [PDF]

				M. Nakae, H. Kamiya, K. Naruse, N. Horio, Y. Ito, R. Mizubayashi, Y. Hamada, E. Nakashima, N. Akiyama, Y. Kobayashi, et al. Effects of basic fibroblast growth factor on experimental diabetic neuropathy in rats. Diabetes, May 1, 2006; 55(5): 1470 - 1477. [Abstract] [Full Text] [PDF]

				R. J. Barbuch, K. Campanale, C. E. Hadden, M. Zmijewski, P. Yi, D. D. O'Bannon, J. L. Burkey, and P. Kulanthaivel IN VIVO METABOLISM OF [14C]RUBOXISTAURIN IN DOGS, MICE, AND RATS FOLLOWING ORAL ADMINISTRATION AND THE STRUCTURE DETERMINATION OF ITS METABOLITES BY LIQUID CHROMATOGRAPHY/MASS SPECTROMETRY AND NMR SPECTROSCOPY Drug Metab. Dispos., February 1, 2006; 34(2): 213 - 224. [Abstract] [Full Text] [PDF]

				M. H. Yoo, H.-J. Hyun, J.-Y. Koh, and Y. H. Yoon Riluzole Inhibits VEGF-Induced Endothelial Cell Proliferation In Vitro and Hyperoxia-Induced Abnormal Vessel Formation In Vivo Invest. Ophthalmol. Vis. Sci., December 1, 2005; 46(12): 4780 - 4787. [Abstract] [Full Text] [PDF]

				S. V Joy, A. C Scates, S. Bearelly, M. Dar, C. A Taulien, J. A Goebel, and M. J Cooney Ruboxistaurin, a Protein Kinase C {beta} Inhibitor, as an Emerging Treatment for Diabetes Microvascular Complications Ann. Pharmacother., October 1, 2005; 39(10): 1693 - 1699. [Abstract] [Full Text] [PDF]

				K. Naruse, Y. Hamada, E. Nakashima, K. Kato, R. Mizubayashi, H. Kamiya, Y. Yuzawa, S. Matsuo, T. Murohara, T. Matsubara, et al. Therapeutic Neovascularization Using Cord Blood-Derived Endothelial Progenitor Cells for Diabetic Neuropathy Diabetes, June 1, 2005; 54(6): 1823 - 1828. [Abstract] [Full Text] [PDF]

				F. Li, V. R. Drel, C. Szabo, M. J. Stevens, and I. G. Obrosova Low-Dose Poly(ADP-Ribose) Polymerase Inhibitor-Containing Combination Therapies Reverse Early Peripheral Diabetic Neuropathy Diabetes, May 1, 2005; 54(5): 1514 - 1522. [Abstract] [Full Text] [PDF]

				M. Andrassy, D. Belov, E. Harja, Y. S. Zou, M. Leitges, H. A. Katus, P. P. Nawroth, S. D. Yan, A. M. Schmidt, and S.-F. Yan Central Role of PKC{beta} in Neointimal Expansion Triggered by Acute Arterial Injury Circ. Res., March 4, 2005; 96(4): 476 - 483. [Abstract] [Full Text] [PDF]

				I. G. Obrosova, P. Pacher, C. Szabo, Z. Zsengeller, H. Hirooka, M. J. Stevens, and M. A. Yorek Aldose Reductase Inhibition Counteracts Oxidative-Nitrosative Stress and Poly(ADP-Ribose) Polymerase Activation in Tissue Sites for Diabetes Complications Diabetes, January 1, 2005; 54(1): 234 - 242. [Abstract] [Full Text] [PDF]

				K. Uehara, S.-I. Yamagishi, S. Otsuki, S. Chin, and S. Yagihashi Effects of Polyol Pathway Hyperactivity on Protein Kinase C Activity, Nociceptive Peptide Expression, and Neuronal Structure in Dorsal Root Ganglia in Diabetic Mice Diabetes, December 1, 2004; 53(12): 3239 - 3247. [Abstract] [Full Text] [PDF]

				V. Brussee, F. A. Cunningham, and D. W. Zochodne Direct Insulin Signaling of Neurons Reverses Diabetic Neuropathy Diabetes, July 1, 2004; 53(7): 1824 - 1830. [Abstract] [Full Text] [PDF]

				H. G. Bohlen Protein kinase {beta}II in Zucker obese rats compromises oxygen and flow-mediated regulation of nitric oxide formation Am J Physiol Heart Circ Physiol, February 1, 2004; 286(2): H492 - H497. [Abstract] [Full Text] [PDF]

				S. M Setter, R K. Campbell, and C. J Cahoon Biochemical Pathways for Microvascular Complications of Diabetes Mellitus Ann. Pharmacother., December 1, 2003; 37(12): 1858 - 1866. [Abstract] [Full Text] [PDF]

				H. Kim, T. Sasaki, K. Maeda, D. Koya, A. Kashiwagi, and H. Yasuda Protein Kinase C{beta} Selective Inhibitor LY333531 Attenuates Diabetic Hyperalgesia Through Ameliorating cGMP Level of Dorsal Root Ganglion Neurons Diabetes, August 1, 2003; 52(8): 2102 - 2109. [Abstract] [Full Text] [PDF]

				I. G. Obrosova, A. G. Minchenko, R. Vasupuram, L. White, O. I. Abatan, A. K. Kumagai, R. N. Frank, and M. J. Stevens Aldose Reductase Inhibitor Fidarestat Prevents Retinal Oxidative Stress and Vascular Endothelial Growth Factor Overexpression in Streptozotocin-Diabetic Rats Diabetes, March 1, 2003; 52(3): 864 - 871. [Abstract] [Full Text] [PDF]

				Z. He, C. Rask-Madsen, and G.L. King Mechanisms of cardiovascular complications in diabetes and potential new pharmacological therapies Eur. Heart J. Suppl., January 1, 2003; 5(suppl_B): B51 - B57. [Abstract] [PDF]

				M. J. Sheetz and G. L. King Molecular Understanding of Hyperglycemia's Adverse Effects for Diabetic Complications JAMA, November 27, 2002; 288(20): 2579 - 2588. [Abstract] [Full Text] [PDF]

				K. V. Ramana, D. Chandra, S. Srivastava, A. Bhatnagar, B. B. Aggarwal, and S. K. Srivastava Aldose Reductase Mediates Mitogenic Signaling in Vascular Smooth Muscle Cells J. Biol. Chem., August 23, 2002; 277(35): 32063 - 32070. [Abstract] [Full Text] [PDF]

				H. G. Bohlen and G. P. Nase Obesity lowers hyperglycemic threshold for impaired in vivo endothelial nitric oxide function Am J Physiol Heart Circ Physiol, July 1, 2002; 283(1): H391 - H397. [Abstract] [Full Text] [PDF]

				D. D. Gutterman Vascular Dysfunction in Hyperglycemia: Is Protein Kinase C the Culprit? Circ. Res., January 11, 2002; 90(1): 5 - 7. [Full Text] [PDF]

				S. Yagihashi, S.-I. Yamagishi, R.-i. Wada, M. Baba, T. C. Hohman, C. Yabe-Nishimura, and Y. Kokai Neuropathy in diabetic mice overexpressing human aldose reductase and effects of aldose reductase inhibitor Brain, December 1, 2001; 124(12): 2448 - 2458. [Abstract] [Full Text] [PDF]

				H. G. Bohlen and G. P. Nase Arteriolar nitric oxide concentration is decreased during hyperglycemia-induced {beta}II PKC activation Am J Physiol Heart Circ Physiol, February 1, 2001; 280(2): H621 - H627. [Abstract] [Full Text] [PDF]

				M. Meier and G. L King Protein kinase C activation and its pharmacological inhibition in vascular disease Vascular Medicine, August 1, 2000; 5(3): 173 - 185. [Abstract] [PDF]

				S.-F. Yan, J. Lu, Y. S. Zou, W. Kisiel, N. Mackman, M. Leitges, S. Steinberg, D. Pinsky, and D. Stern Protein Kinase C-beta and Oxygen Deprivation. A NOVEL Egr-1-DEPENDENT PATHWAY FOR FIBRIN DEPOSITION IN HYPOXEMIC VASCULATURE J. Biol. Chem., April 14, 2000; 275(16): 11921 - 11928. [Abstract] [Full Text] [PDF]

				R. Sakthivel, J.-C. Zhang, D. K. Strickland, M. Gafvels, and K. R. McCrae Regulation of the Ligand Binding Activity of the Human Very Low Density Lipoprotein Receptor by Protein Kinase C-dependent Phosphorylation J. Biol. Chem., January 5, 2001; 276(1): 555 - 562. [Abstract] [Full Text] [PDF]